Celsion Co. (CLSN) CEO Michael H. Tardugno Purchases 7,500 Shares
Celsion Co. (NASDAQ:CLSN) CEO Michael H. Tardugno bought 7,500 shares of the firm’s stock in a transaction dated Monday, March 5th. The shares were purchased at an average price of $2.38 per share, with a total value of $17,850.00. Following the acquisition, the chief executive officer now directly owns 17,700 shares in the company, valued at approximately $42,126. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Celsion Co. (NASDAQ CLSN) traded up $0.19 during midday trading on Monday, reaching $2.44. The company’s stock had a trading volume of 617,635 shares, compared to its average volume of 363,086. The stock has a market cap of $39.90, a PE ratio of -0.41 and a beta of 1.80. Celsion Co. has a 52-week low of $1.24 and a 52-week high of $6.06.
A number of analysts have recently issued reports on the company. ValuEngine cut Celsion from a “sell” rating to a “strong sell” rating in a report on Wednesday, November 15th. Zacks Investment Research cut Celsion from a “buy” rating to a “hold” rating in a report on Thursday, January 11th. Finally, Oppenheimer assumed coverage on Celsion in a report on Tuesday, November 21st. They set an “outperform” rating and a $9.00 target price for the company. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $11.90.
ILLEGAL ACTIVITY NOTICE: “Celsion Co. (CLSN) CEO Michael H. Tardugno Purchases 7,500 Shares” was published by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2018/03/05/celsion-co-clsn-ceo-michael-h-tardugno-purchases-7500-shares.html.
Celsion Company Profile
Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).
Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.